CLINICAL_TRIALS trial_result · 2012-12-17

Clinical Trial Update: Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis [Phase 2, Phase 3]

Pfizer's Fx-1006A completed a Phase 2/3 study in Familial Amyloid Polyneuropathy, with safety and efficacy results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Pfizer | Conditions: Familial Amyloid Polyneuropathy | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2012-12-17